Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 8/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620445 | 1.00 | CYP2D6 (0.50) | CYP2D6ITGB3ITGA2BALDH1A1CYP3A4 | |
| SCHEMBL6620319 | 0.89 | ITGB3 (0.51) | ITGB3ITGA2BTSHR | |
| SCHEMBL6620316 | 0.89 | ITGB3 (0.51) | ITGB3ITGA2BTSHR | |
| SCHEMBL6622584 | 0.88 | ITGB3 (0.49) | ITGB3ITGA2B | |
| SCHEMBL6622583 | 0.88 | ITGB3 (0.49) | ITGB3ITGA2B | |
| SCHEMBL7149068 | 0.87 | ITGB3 (0.58) | CYP2D6ITGB3ITGA2BALDH1A1CYP3A4 | |
| Acetic Acid SCHEMBL6621008 | 0.86 | ITGB3 (0.53) | CYP2D6ITGB3ITGA2B | |
| SCHEMBL6778113 | 0.80 | ITGB3 (0.43) | ITGB3ITGA2BTSHR | |
| SCHEMBL6778116 | 0.80 | ITGB3 (0.43) | ITGB3ITGA2BTSHR | |
| SCHEMBL7147856 | 0.77 | MMP2 (0.58) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0854869-B1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | LILLY CO ELI (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6693109-B2 | SUCH AS ETHYL(3-(4-(AMINOIMINOMETHYL)PHENYL)-1-OXA-2,8-DIAZA-SPIRO(4.5)DEC-2-EN-8 -YL)ACETATE | ELI LILLY AND COMPANY | 2004-02-17 | — | — | US | disclosed |
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | FISHER MATTHEW J (US) | 2003-09-11 | — | — | US | disclosed |
| US-6291469-B1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | ELI LILLY AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| EP-0854869-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997011940-A1 | SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | ELI LILLY AND COMPANY (US) | 1997-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171373-A1 | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, SELP | CYP2D6 3270/4885ITGB3 57/4885ITGA2B 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.